Information Provided By: 
Fly News Breaks for May 15, 2019
ADAP, ALPN
May 15, 2019 | 09:58 EDT
After Alpine Immune Sciences (ALPN) announced a partnership with Adaptimmune (ADAP) to incorporate its novel Transmembrane and Secreted Immunomodulatory Proteins, or TIPs and SIPs, into CAR-T cells, Piper Jaffray analyst Edward Tenthoff said he sees Alpine having broad potential to partner its TIPs and SIPs for next generation cellular therapies. The analyst, who noted that Alpine is also advancing a platform of novel variant Ig domains, or "vIgDs," to augment T-cell activation, keeps an Overweight rating and $11 price target on Alpine shares.
News For ALPN;ADAP From the Last 2 Days
There are no results for your query ALPN;ADAP
